A new slow-release pill form of ketamine can quell hard-to-treat depression without producing psychedelic side effects normally associated with the drug, early research suggests.
without producing psychedelic side effects normally associated with the drug, early research suggests.compared to a placebo, researchers found.scale, people taking the ketamine pill improved by 14 points, while the placebo group had an average reduction of 8 points.
A derivative of ketamine called esketamine is already approved in the United States for treatment-resistant depression “That's very similar to the psychedelic-assisted therapy model that says changing your brain circuit functioning in that very profound way gives you new insights that help you to break out of your way of thinking, and that this acute kind of dissociative, altered reality experience is necessary for you to improve,” Loo said.
Researchers then zeroed in on the people who had responded to extended-release ketamine, randomly assigning them into one of five groups. Four of the groups received different strengths of extended-release ketamine pills, and one received a placebo. “The results here, they look encouraging,” Dr. Brian Barnett, clinical director of the Psychiatric Treatment Resistance Program at the Cleveland Clinic, toldBarnett noted that a two-point drop in the depression rating scale used in this study is considered meaningful to patients.of psilocybin for treatment-resistant depression,” Barnett said, referring to studies of “magic” mushrooms and depression.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
A ketamine pill may help hard-to-treat depression with fewer side effects, early research suggestsA new ketamine pill may help hard-to-treat depression with fewer side effects than other forms of the treatment, early research suggests.
Les mer »
Oral Extended-Release Ketamine Promising for Treatment-Resistant DepressionExtended-release ketamine tablets taken twice weekly was effective for treatment-resistant depression with fewer side effects compared with intravenous or intranasal ketamine in a phase 2 trial.
Les mer »
Trump yet to clarify his abortion pill policy as SCOTUS rules on mifepristoneTrump has said he'd soon release abortion pill policy details, but hasn't yet.
Les mer »
Implementing FIT21 could be a ‘slow, slow process’ — CFTC CommissionerIf FIT21 is enacted, CFTC Commissioner Mersinger anticipates extensive coordination and potential delays in its implementation across U.S. regulatory agencies.
Les mer »
LAPD under fire for slow release of crime logsThe Los Angeles Police Department is the last of the big-city agencies to make the switch to the FBI's National Incident-Based Reporting System.
Les mer »
Utah’s lethal injection cocktail will include ketamine, fentanylUtah will include ketamine and fentanyl in its three-drug lethal injection cocktail — a combination that a death row inmate's attorney argues are 'experimental' and 'untested.'
Les mer »